XML 11 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 47,978 $ 22,895
Accounts receivable, net 438 302
Receivable from Sanofi   30,557
Inventory 3,698 2,331
Asset held for sale   16,730
Deferred costs from commercial product sales 472 309
Prepaid expenses and other current assets 3,508 4,364
Total current assets 56,094 77,488
Property and equipment - net 28,482 28,927
Other assets 609 648
Total assets 85,185 107,063
Current liabilities:    
Accounts payable 1,519 3,263
Accrued expenses and other current liabilities 10,657 7,937
Facility financing obligation 71,795 71,339
Deferred revenue - net 1,844 3,419
Deferred payments from collaboration - current 250 1,000
Recognized loss on purchase commitments - current 6,984 5,093
Total current liabilities 93,049 92,051
Note payable to principal stockholder 49,521 49,521
Accrued interest - note payable to principal stockholder 9,995 9,281
Senior convertible notes 27,642 27,635
Recognized loss on purchase commitments - long term 95,062 95,942
Deferred payments from collaboration - long term 687  
Warrant liability 752 7,381
Milestone rights liability and other liabilities 7,202 8,845
Total liabilities 283,910 290,656
Commitments and contingencies (Note 10)
Stockholders' deficit:    
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding at March 31, 2017 and December 31, 2016
Common stock, $0.01 par value - 140,000,000 shares authorized, 95,776,297 and 95,680,831 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively 958 957
Additional paid-in capital 2,554,230 2,553,039
Accumulated other comprehensive loss (24) (24)
Accumulated deficit (2,753,889) (2,737,565)
Total stockholders' deficit (198,725) (183,593)
Total liabilities and stockholders' deficit $ 85,185 $ 107,063